Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma

Inclusion Criteria: * Histologically confirmed newly diagnosed embryonal rhabdomyosarcoma (RMS), botryoid or spindle cell variants of embryonal RMS, or embryonal ectomesenchymoma, meeting criteria for 1 of the following subsets: * Subset 1, defined by meeting 1 of the following criteria (closed to accrual as of 08/13/2010): * Stage 1 and clinical group I (completely resected) or II (microscopic residual disease and/or regional lymph node involvement) disease * Stage 1 and clinical group III (gross residual disease) disease arising in the orbit * Stage 2 and clinical group I or II disease * Subset 2, defined by meeting 1 of the following criteria (closed to accrual as of 09/23/2011): * Stage 1 and clinical group III disease arising in a non-orbit site * Stage 3 and clinical group I or II disease * Prior staging ipsilateral retroperitoneal lymph node dissection required for all patients age 10 and over with paratesticular tumors and patients under 10 years of age with clinically or radiographically involved lymph nodes (except when extensive lymph node involvement is identified by imaging studies) * If there is extensive gross node involvement only confirmatory node biopsy is recommended and the patient is classified as Clinical Group III * Prior regional lymph node sampling required for patients with extremity tumors * None of the following diagnoses: * Intermediate-risk embryonal RMS * Metastatic embryonal RMS * Alveolar RMS * Undiffere…